Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
The pharmacokinetics of cidofovir (HPMPC; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine) were examined at five dose levels in three phase I/II studies in a total of 42 human immunodeficiency virus-infected patients (with or without asymptomatic cytomegalovirus infection). Levels of cidofovir...
Furkejuvvon:
| Publikašuvnnas: | Antimicrob Agents Chemother |
|---|---|
| Váldodahkkit: | , , , , , , , , , |
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
American Society for Microbiology (ASM)
1995
|
| Fáttát: | |
| Liŋkkat: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162721/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7574510/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.6.1247 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
